What is Jyong Biotech Ltd.'s earnings per share (EPS)?

Jyong Biotech Ltd. (MENS) reported diluted earnings per share of $-0.06 for fiscal year 2025. This represents a -50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jyong Biotech Ltd. Financials

MENS

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows Jyong Biotech Ltd. (MENS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating Jyong Biotech Ltd.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Jyong Biotech Ltd. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.65x

For every $1 of reported earnings, Jyong Biotech Ltd. generates $0.65 in operating cash flow (-$3.0M OCF vs -$4.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1.0x

Jyong Biotech Ltd. earns $-1.0 in operating income for every $1 of interest expense (-$2.6M vs $2.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$2.5M

YoY-29.5%

Jyong Biotech Ltd.'s EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 29.5% from the prior year.

Net Income

-$4.7M

YoY-54.7%

Jyong Biotech Ltd. reported -$4.7M in net income in fiscal year 2025. This represents a decrease of 54.7% from the prior year.

EPS (Diluted)

$-0.06

YoY-50.0%

Jyong Biotech Ltd. earned $-0.06 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 50.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.2M

YoY+1066.3%

Jyong Biotech Ltd. held $1.2M in cash against $2.1M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

76M

YoY+3.6%

Jyong Biotech Ltd. had 76M shares outstanding in fiscal year 2025. This represents an increase of 3.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$813K

YoY-12.3%

Jyong Biotech Ltd. invested $813K in research and development in fiscal year 2025. This represents a decrease of 12.3% from the prior year.

Share Buybacks

$16.4M

Jyong Biotech Ltd. spent $16.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

MENS Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	$813K-12.3%	$927K-13.4%	$1.1M
SG&A Expenses	$1.7M+61.2%	$1.1M-35.4%	$1.7M
Operating Income	-$2.6M-26.8%	-$2.1M+26.5%	-$2.8M
Interest Expense	$2.5M+145.3%	$1.0M+36.7%	$757K
Income Tax	N/A	N/A	N/A
Net Income	-$4.7M-54.7%	-$3.0M+31.4%	-$4.4M
EPS (Diluted)	$-0.06-50.0%	$-0.04+33.3%	$-0.06

Metric	Q4'25	Q4'24
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

MENS Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$20.8M+226.4%	$6.4M	N/A
Current Assets	$15.5M+7444.7%	$206K	N/A
Cash & Equivalents	$1.2M+1066.3%	$101K-94.2%	$1.7M
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$45.7M+6.5%	$42.9M	N/A
Current Liabilities	$34.8M+187.0%	$12.1M	N/A
Long-Term Debt	$2.1M	N/A	N/A
Total Equity	-$24.9M+31.8%	-$36.5M-7.2%	-$34.1M
Retained Earnings	-$37.8M-14.1%	-$33.1M-10.0%	-$30.1M

Metric	Q4'25	Q4'24
Total Assets	$20.8M+226.4%	$6.4M
Current Assets	$15.5M+7444.7%	$206K
Cash & Equivalents	$1.2M+1066.3%	$101K
Inventory	N/A	N/A
Accounts Receivable	N/A	N/A
Goodwill	N/A	N/A
Total Liabilities	$45.7M+6.5%	$42.9M
Current Liabilities	$34.8M+187.0%	$12.1M
Long-Term Debt	$2.1M	N/A
Total Equity	-$24.9M+31.8%	-$36.5M
Retained Earnings	-$37.8M-14.1%	-$33.1M

MENS Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$3.0M+16.1%	-$3.6M-39.3%	-$2.6M
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	-$13.5M	N/A	$95K
Financing Cash Flow	$17.6M+786.1%	$2.0M-1.9%	$2.0M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	$16.4M	N/A	N/A

Metric	Q4'25	Q4'24
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

MENS Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A
Return on Assets	-22.5%+24.9pp	-47.4%	N/A
Current Ratio	0.45+0.4	0.02	N/A
Debt-to-Equity	-0.09+1.1	-1.17	N/A
FCF Margin	N/A	N/A	N/A

Metric	Q4'25	Q4'24
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	0.45+0.4	0.02
Debt-to-Equity	-0.09+1.1	-1.17
FCF Margin	N/A	N/A

Note: Shareholder equity is negative (-$24.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.45), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Tg Therapeutics Inc TGTX

$9.0B

Crispr Therapeut CRSP

$5.5B

Ptc Therapeutics PTCT

$7.4B

Atrium Therapeutics, Inc RNA

$220.8M

Merus MRUS

$6.8B

Frequently Asked Questions

Is Jyong Biotech Ltd. profitable?

No, Jyong Biotech Ltd. (MENS) reported a net income of -$4.7M in fiscal year 2025.

What is Jyong Biotech Ltd.'s EBITDA?

Jyong Biotech Ltd. (MENS) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Jyong Biotech Ltd. have?

As of fiscal year 2025, Jyong Biotech Ltd. (MENS) had $1.2M in cash and equivalents against $2.1M in long-term debt.

What is Jyong Biotech Ltd.'s operating cash flow?

Jyong Biotech Ltd. (MENS) generated -$3.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Jyong Biotech Ltd.'s total assets?

Jyong Biotech Ltd. (MENS) had $20.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Jyong Biotech Ltd. spend on research and development?

Jyong Biotech Ltd. (MENS) invested $813K in research and development during fiscal year 2025.

Does Jyong Biotech Ltd. buy back shares?

Yes, Jyong Biotech Ltd. (MENS) spent $16.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Jyong Biotech Ltd. have outstanding?

Jyong Biotech Ltd. (MENS) had 76M shares outstanding as of fiscal year 2025.

What is Jyong Biotech Ltd.'s current ratio?

Jyong Biotech Ltd. (MENS) had a current ratio of 0.45 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Jyong Biotech Ltd.'s debt-to-equity ratio?

Jyong Biotech Ltd. (MENS) had a debt-to-equity ratio of -0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jyong Biotech Ltd.'s return on assets (ROA)?

Jyong Biotech Ltd. (MENS) had a return on assets of -22.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jyong Biotech Ltd.'s cash runway?

Based on fiscal year 2025 data, Jyong Biotech Ltd. (MENS) had $1.2M in cash against an annual operating cash burn of $3.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Jyong Biotech Ltd.'s debt-to-equity ratio negative or unusual?

Jyong Biotech Ltd. (MENS) has negative shareholder equity of -$24.9M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Jyong Biotech Ltd.'s Piotroski F-Score?

Jyong Biotech Ltd. (MENS) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jyong Biotech Ltd.'s earnings high quality?

Jyong Biotech Ltd. (MENS) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Jyong Biotech Ltd. cover its interest payments?

Jyong Biotech Ltd. (MENS) has an interest coverage ratio of -1.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.